Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

Anticoagulant therapy is the cornerstone of treatment and prevention of arterial and venous
thromboembolism. Taking a historical perspective, starting in the 1960s, and progressing …

Background Effective stroke prevention with oral anticoagulants (OAC) is recommended for
some patients with atrial fibrillation (AF). We aimed to describe OAC use by geographical …

Aims To compare the effectiveness and safety of off-label underdosed apixaban with on-
label standard dose apixaban in Asian patients with atrial fibrillation (AF). Methods and …

Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …

Introduction For a long time, vitamin K antagonists (VKA) were the only oral anticoagulation
therapy available to reduce adverse events in atrial fibrillation (AF) patients. Direct-acting …

Objective Assessment of generalisability of guideline-informing trials on antithrombotic
treatment intensification to real-world patients with cardiovascular disease (CVD). Methods …

The aim was to identify sex‐specific factors linked with oral anticoagulant initiation in a
cohort of patients with atrial fibrillation using administrative data from Quebec (Canada) …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …

Patients with high body weight are at increased risk of developing atrial fibrillation (AF) or
venous thromboembolism (VTE) and are often treated with antithrombotic drugs. 1 Direct …